影像引导下铅笔束扫描质子束疗法对脊索瘤和软骨肉瘤早期疗效的影响

IF 2.2 Q3 ONCOLOGY
Srinivas Chilukuri MD , Nagarjuna Burela MD , Sham Sundar MD , Ramakrishna Kamath MD , Sapna Nangia MD , Manikandan Arjunan MSc, PhD , Roopesh Kumar MS, MCh , Vishnu Ramanujam MS , Ari Chacko , Dayananda Shamurailatpam Sharma MSc, PhD , Rakesh Jalali MD
{"title":"影像引导下铅笔束扫描质子束疗法对脊索瘤和软骨肉瘤早期疗效的影响","authors":"Srinivas Chilukuri MD ,&nbsp;Nagarjuna Burela MD ,&nbsp;Sham Sundar MD ,&nbsp;Ramakrishna Kamath MD ,&nbsp;Sapna Nangia MD ,&nbsp;Manikandan Arjunan MSc, PhD ,&nbsp;Roopesh Kumar MS, MCh ,&nbsp;Vishnu Ramanujam MS ,&nbsp;Ari Chacko ,&nbsp;Dayananda Shamurailatpam Sharma MSc, PhD ,&nbsp;Rakesh Jalali MD","doi":"10.1016/j.adro.2024.101582","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To critically review the clinical factors, dosimetry, and their correlation with early outcomes in patients with chordomas and chondrosarcomas treated with pencil beam scanning (PBS) proton beam therapy (PBT).</p></div><div><h3>Methods and Materials</h3><p>Consecutive 64 patients diagnosed with chordoma or chondrosarcoma treated at our center were studied. Patient, tumor, and treatment-related factors including dosimetry were captured. Early and late toxicities and early outcomes were evaluated and correlated with clinical and dosimetric factors using standard statistical tools.</p></div><div><h3>Results</h3><p>The median age of patients was 39 years (range, 4-74 years), and most common site was skull base (47%), followed by sacrum (31%) and mobile spine (22%). The median prescription dose to the high-risk clinical target volumes for chordoma and chondrosarcoma was 70.4 cobalt gray equivalent (CGE) and 66 CGE at 2.2 CGE per fraction, respectively. At presentation, 55% presented after a recurrence/progression of which 17% had received previous radiation and 32% had a significant neural compression. At the time of PBT, 25% of patients had suboptimal neural separation. Three-fourths of patients had at least an acceptable target coverage. Although 11% had a tier 1 compromise (gross tumor volume [GTV] D98 &lt; 90%), 14% had a tier 2 compromise (GTVD98 &lt; 59 CGE). With a median follow-up of 27.5 months, 2-year local control and progression-free survival was 86.7% and 81.8% for chordomas and 87.5% and 77.1% for chondrosarcomas, respectively. Residual GTV of &gt;25 cm<sup>3</sup> and a tier 2 compromise were associated with inferior local control (hazard ratio [HR], 0.19; <em>P</em> = .019; HR, 0.061; <em>P</em> = .022, respectively) and progression-free survival (HR, 0.128; <em>P</em> = 0.014; HR, 0.194; <em>P</em> =.025, respectively) on multivariate analysis. Despite multiple surgeries, a majority presented with recurrent disease and previous radiations and grade 3 acute and late toxicities were limited and comparable with others in the literature.</p></div><div><h3>Conclusions</h3><p>Despite multiple surgeries, adequate neural separation was challenging to achieve. Severe dosimetric compromise (GTV D98 &lt; 59 CGE) led to inferior early outcomes. Adequate neural separation is key to avoiding dosimetric compromise and achieving optimal local control.</p></div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"9 10","pages":"Article 101582"},"PeriodicalIF":2.2000,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2452109424001453/pdfft?md5=046bb758839ce8dfda1ffa7c2fcb3b88&pid=1-s2.0-S2452109424001453-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Impact of Dosimetric Compromises on Early Outcomes of Chordomas and Chondrosarcomas Treated With Image-guided Pencil Beam Scanning Proton Beam Therapy\",\"authors\":\"Srinivas Chilukuri MD ,&nbsp;Nagarjuna Burela MD ,&nbsp;Sham Sundar MD ,&nbsp;Ramakrishna Kamath MD ,&nbsp;Sapna Nangia MD ,&nbsp;Manikandan Arjunan MSc, PhD ,&nbsp;Roopesh Kumar MS, MCh ,&nbsp;Vishnu Ramanujam MS ,&nbsp;Ari Chacko ,&nbsp;Dayananda Shamurailatpam Sharma MSc, PhD ,&nbsp;Rakesh Jalali MD\",\"doi\":\"10.1016/j.adro.2024.101582\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>To critically review the clinical factors, dosimetry, and their correlation with early outcomes in patients with chordomas and chondrosarcomas treated with pencil beam scanning (PBS) proton beam therapy (PBT).</p></div><div><h3>Methods and Materials</h3><p>Consecutive 64 patients diagnosed with chordoma or chondrosarcoma treated at our center were studied. Patient, tumor, and treatment-related factors including dosimetry were captured. Early and late toxicities and early outcomes were evaluated and correlated with clinical and dosimetric factors using standard statistical tools.</p></div><div><h3>Results</h3><p>The median age of patients was 39 years (range, 4-74 years), and most common site was skull base (47%), followed by sacrum (31%) and mobile spine (22%). The median prescription dose to the high-risk clinical target volumes for chordoma and chondrosarcoma was 70.4 cobalt gray equivalent (CGE) and 66 CGE at 2.2 CGE per fraction, respectively. At presentation, 55% presented after a recurrence/progression of which 17% had received previous radiation and 32% had a significant neural compression. At the time of PBT, 25% of patients had suboptimal neural separation. Three-fourths of patients had at least an acceptable target coverage. Although 11% had a tier 1 compromise (gross tumor volume [GTV] D98 &lt; 90%), 14% had a tier 2 compromise (GTVD98 &lt; 59 CGE). With a median follow-up of 27.5 months, 2-year local control and progression-free survival was 86.7% and 81.8% for chordomas and 87.5% and 77.1% for chondrosarcomas, respectively. Residual GTV of &gt;25 cm<sup>3</sup> and a tier 2 compromise were associated with inferior local control (hazard ratio [HR], 0.19; <em>P</em> = .019; HR, 0.061; <em>P</em> = .022, respectively) and progression-free survival (HR, 0.128; <em>P</em> = 0.014; HR, 0.194; <em>P</em> =.025, respectively) on multivariate analysis. Despite multiple surgeries, a majority presented with recurrent disease and previous radiations and grade 3 acute and late toxicities were limited and comparable with others in the literature.</p></div><div><h3>Conclusions</h3><p>Despite multiple surgeries, adequate neural separation was challenging to achieve. Severe dosimetric compromise (GTV D98 &lt; 59 CGE) led to inferior early outcomes. Adequate neural separation is key to avoiding dosimetric compromise and achieving optimal local control.</p></div>\",\"PeriodicalId\":7390,\"journal\":{\"name\":\"Advances in Radiation Oncology\",\"volume\":\"9 10\",\"pages\":\"Article 101582\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2452109424001453/pdfft?md5=046bb758839ce8dfda1ffa7c2fcb3b88&pid=1-s2.0-S2452109424001453-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Radiation Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2452109424001453\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452109424001453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的对在本中心接受铅笔束扫描(PBS)质子束治疗(PBT)的脊索瘤和软骨肉瘤患者的临床因素、剂量测定及其与早期疗效的相关性进行批判性研究。收集了患者、肿瘤和治疗相关因素(包括剂量测定)。结果患者的中位年龄为39岁(4-74岁),最常见的部位是颅底(47%),其次是骶骨(31%)和活动脊柱(22%)。脊索瘤和软骨肉瘤高风险临床靶体积的处方剂量中位数分别为70.4钴灰当量(CGE)和66钴灰当量,每分2.2钴灰当量。55%的患者是在复发/进展后就诊,其中17%的患者曾接受过放射治疗,32%的患者有明显的神经压迫症状。在进行 PBT 时,25% 的患者神经分离不理想。四分之三的患者至少有可接受的目标覆盖范围。虽然有11%的患者出现了一级损害(肿瘤总体积[GTV] D98 <90%),但有14%的患者出现了二级损害(GTVD98 <59CGE)。中位随访时间为27.5个月,脊索瘤的2年局部控制率和无进展生存率分别为86.7%和81.8%,软骨肉瘤的2年局部控制率和无进展生存率分别为87.5%和77.1%。在多变量分析中,残留 GTV 为 25 cm3 和二级妥协与较差的局部控制率(危险比 [HR],0.19;P = 0.019;HR,0.061;P = 0.022)和无进展生存率(HR,0.128;P = 0.014;HR,0.194;P = 0.025)相关。尽管进行了多次手术,但大多数患者都出现了疾病复发和既往放射治疗,3级急性和晚期毒性反应有限,与其他文献中的结果相当。严重的剂量学损害(GTV D98 < 59 CGE)导致早期疗效不佳。充分的神经分离是避免剂量受损和实现最佳局部控制的关键。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of Dosimetric Compromises on Early Outcomes of Chordomas and Chondrosarcomas Treated With Image-guided Pencil Beam Scanning Proton Beam Therapy

Purpose

To critically review the clinical factors, dosimetry, and their correlation with early outcomes in patients with chordomas and chondrosarcomas treated with pencil beam scanning (PBS) proton beam therapy (PBT).

Methods and Materials

Consecutive 64 patients diagnosed with chordoma or chondrosarcoma treated at our center were studied. Patient, tumor, and treatment-related factors including dosimetry were captured. Early and late toxicities and early outcomes were evaluated and correlated with clinical and dosimetric factors using standard statistical tools.

Results

The median age of patients was 39 years (range, 4-74 years), and most common site was skull base (47%), followed by sacrum (31%) and mobile spine (22%). The median prescription dose to the high-risk clinical target volumes for chordoma and chondrosarcoma was 70.4 cobalt gray equivalent (CGE) and 66 CGE at 2.2 CGE per fraction, respectively. At presentation, 55% presented after a recurrence/progression of which 17% had received previous radiation and 32% had a significant neural compression. At the time of PBT, 25% of patients had suboptimal neural separation. Three-fourths of patients had at least an acceptable target coverage. Although 11% had a tier 1 compromise (gross tumor volume [GTV] D98 < 90%), 14% had a tier 2 compromise (GTVD98 < 59 CGE). With a median follow-up of 27.5 months, 2-year local control and progression-free survival was 86.7% and 81.8% for chordomas and 87.5% and 77.1% for chondrosarcomas, respectively. Residual GTV of >25 cm3 and a tier 2 compromise were associated with inferior local control (hazard ratio [HR], 0.19; P = .019; HR, 0.061; P = .022, respectively) and progression-free survival (HR, 0.128; P = 0.014; HR, 0.194; P =.025, respectively) on multivariate analysis. Despite multiple surgeries, a majority presented with recurrent disease and previous radiations and grade 3 acute and late toxicities were limited and comparable with others in the literature.

Conclusions

Despite multiple surgeries, adequate neural separation was challenging to achieve. Severe dosimetric compromise (GTV D98 < 59 CGE) led to inferior early outcomes. Adequate neural separation is key to avoiding dosimetric compromise and achieving optimal local control.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in Radiation Oncology
Advances in Radiation Oncology Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
4.60
自引率
4.30%
发文量
208
审稿时长
98 days
期刊介绍: The purpose of Advances is to provide information for clinicians who use radiation therapy by publishing: Clinical trial reports and reanalyses. Basic science original reports. Manuscripts examining health services research, comparative and cost effectiveness research, and systematic reviews. Case reports documenting unusual problems and solutions. High quality multi and single institutional series, as well as other novel retrospective hypothesis generating series. Timely critical reviews on important topics in radiation oncology, such as side effects. Articles reporting the natural history of disease and patterns of failure, particularly as they relate to treatment volume delineation. Articles on safety and quality in radiation therapy. Essays on clinical experience. Articles on practice transformation in radiation oncology, in particular: Aspects of health policy that may impact the future practice of radiation oncology. How information technology, such as data analytics and systems innovations, will change radiation oncology practice. Articles on imaging as they relate to radiation therapy treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信